Editor's Choice
Guidelines for reporting observational research in urology | The importance of clear reference to causality
12 Jun, 2023 | 13:50h | UTC
RCT | Multivitamin supplementation may improve memory in aged adults
7 Jun, 2023 | 14:12h | UTCMultivitamin Supplementation Improves Memory in Older Adults: A Randomized Clinical Trial – The American Journal of Clinical Nutrition (link to abstract – $ for full-text)
News Releases:
Multivitamin Improves Memory in Older Adults, Study Finds – Columbia University
Related Research: Effects of cocoa extract and a multivitamin on cognitive function: A randomized clinical trial – Alzheimer’s & Dementia
SR | Limited evidence for vitamin and mineral supplements in delaying dementia in people with mild cognitive impairment
7 Jun, 2023 | 14:09h | UTC
Commentary on Twitter
🔎 How does vitamin and mineral supplementation affect #cognitivefunction and progression to #dementia in people with mild cognitive impairment (MCI)?
Get the current evidence picture in this #systematicreview on @CochraneLibrary: https://t.co/YUsbjELIZq@NIH_ODS #NSHFD pic.twitter.com/hRl27Tm7op— Cochrane CAM (@CochraneCAM) May 31, 2023
Review | Reducing the carbon footprint and resource use of critical care
7 Jun, 2023 | 14:07h | UTCTowards net zero: critical care – The BMJ (free for a limited period)
Commentary on Twitter
ICUs are a considerable contributor to the carbon footprint of hospitals.
This article and #BMJInfographic present ways to reduce wastehttps://t.co/F2DPQcFnCy pic.twitter.com/bHwu9YZEgo
— The BMJ (@bmj_latest) June 3, 2023
RCT | Preoperative FOLFOX noninferior to chemoradiotherapy in locally advanced rectal cancer
7 Jun, 2023 | 14:06h | UTCPreoperative Treatment of Locally Advanced Rectal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Related Publication: Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048) – Journal of Clinical Oncology
Commentary: Radiation May Be Safely Omitted in Select Patients With Locally Advanced Rectal Cancer – The ASCO Post
Commentary on Twitter
Original Article: Preoperative Treatment of Locally Advanced Rectal Cancer (PROSPECT) https://t.co/6ubagrEzyw#ASCO23 pic.twitter.com/g2XFBkEk4T
— NEJM (@NEJM) June 5, 2023
RCT | Vorasidenib enhances PFS in IDH1/2-mutant low-grade glioma, trial methods debated online
7 Jun, 2023 | 14:04h | UTCVorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Vorasidenib Delays Disease Progression or Death in Patients With Grade 2 IDH-Mutated Glioma – The ASCO Post
Commentary on Twitter questioning study methodology (thread – click for more)
This is a rather troubling study. The fact that it got published in @NEJM is concerning, to say the least
Astonishing cost of $16 000/month for a drug administered continuously until disease progression in a trial with a dubious endpoint and flawed design
Here are my thoughts: https://t.co/E3QtZfEyQw
— Stanislav (Stas) Lazarev, MD (@StasLazarev) June 5, 2023
RCT | Immediate vs. delayed sequential bilateral cataract surgery: non-inferior in safety, higher cost-effectiveness
6 Jun, 2023 | 14:41h | UTCSafety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial – The Lancet (link to abstract – $ for full-text)
News Release: Cataract surgery: two-sided treatment better than one-by-one approach – Maastricht University
RCT | Tirzepatide outperforms insulin glargine in HbA1c reduction and weight loss in type 2 diabetes
6 Jun, 2023 | 14:39h | UTC
Commentary on Twitter
The SURPASS-AP-Combo trial shows that addition of #tirzepatide as 2L or 3L therapy is non-inferior & superior to insulin glargine for glycemic outcomes at 40 weeks in an Asia-Pacific (mostly Chinese) population w/ type 2 #diabetes. https://t.co/RDh2WSJ1wZ pic.twitter.com/nm6pPpVdxH
— Nature Medicine (@NatureMedicine) June 2, 2023
Review | How to understand the 95% confidence interval around the relative risk, odds ratio, and hazard ratio
6 Jun, 2023 | 14:37h | UTC
RCT | Perioperative pembrolizumab improves pathological outcomes, event-free survival in early-stage NSCLC
6 Jun, 2023 | 14:36h | UTCPerioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Presented at #ASCO23: In the KEYNOTE-671 trial, pts with resectable lung cancer were assigned to neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo. Two-year event-free survival was 62.4% with pembrolizumab & 40.6% with placebo.
— NEJM (@NEJM) June 3, 2023
RCT | Tirofiban results in greater likelihood of excellent outcome vs. aspirin in stroke without large vessel occlusion
6 Jun, 2023 | 14:33h | UTCTirofiban for Stroke without Large or Medium-Sized Vessel Occlusion – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Tirofiban for Stroke Without Large or Medium Vessel Occlusion – American College of Cardiology
Commentary on Twitter
Original Article: Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion (RESCUE BT2) https://t.co/Ul2kfAt9yX
Editorial: Expanding Treatment for Acute Ischemic Stroke beyond Revascularization: https://t.co/G8SAWnGJhS pic.twitter.com/21n0x4YqvK
— NEJM (@NEJM) June 1, 2023
Global burden, risk factors analysis, and prediction study of ischemic stroke, 1990–2030
5 Jun, 2023 | 13:53h | UTCGlobal Burden, Risk Factors Analysis, and Prediction Study of Ischemic Stroke, 1990–2030 – Neurology
News Release: Worldwide Stroke Deaths Expected to Increase to Nearly 5 Million by 2030 – American Academy of Neurology
Commentary on Twitter
Published online: Global Burden, Risk Factors Analysis, and Prediction Study of Ischemic #Stroke, 1990–2030 https://t.co/nIH5mBQDtE#NeuroTwitter pic.twitter.com/WUfFQM5t7Z
— Neurology Journal (@GreenJournal) May 23, 2023
RCT | Noninferiority shown between DOACs and LMWH for recurrent VTE prevention in cancer patients
5 Jun, 2023 | 13:50h | UTCSummary: This unblinded, pragmatic, noninferiority randomized clinical trial aimed to assess the efficacy of direct oral anticoagulants (DOACs) against low-molecular-weight heparin (LMWH) in preventing recurrent venous thromboembolism (VTE) in patients with cancer. The study included 671 patients from 67 oncology centers, with a new clinical or radiological diagnosis of VTE.
Participants were randomly assigned to receive either a DOAC or LMWH for 6 months, and treating physicians selected and prescribed the drugs based on considerations like availability and drug-drug interactions. The primary outcome was the rate of recurrent VTE at 6 months. Findings revealed that the DOAC group had a recurrent VTE rate of 6.1% as compared to 8.8% in the LMWH group, showing noninferiority. Both groups had statistically similar rates of major bleeding and severe adverse events.
This pragmatic study included patients with advanced cancer and brain metastases, impaired performance status, and reduced liver or kidney function, making it more representative of routine oncology practice. Moreover, patient adherence to DOAC treatment was significantly higher than to LMWH. Nevertheless, the study had limitations, including the lack of blinding and underrepresentation of certain racial and ethnic groups.
In conclusion, this trial suggests that DOACs were noninferior to LMWH for preventing recurrent VTE in patients with cancer over a 6-month follow-up period, supporting the use of DOACs in this population for VTE prevention. Further research is needed to confirm these results and investigate long-term outcomes.
Article: Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)
See also: Visual abstract
Commentary on Twitter
Among adults with cancer and VTE, direct oral anticoagulants were noninferior to low-molecular-weight heparin for preventing recurrent VTE over 6-month follow-up. #ASCO23 https://t.co/DP5RvlSYxe pic.twitter.com/rBJ99plopK
— JAMA (@JAMA_current) June 2, 2023
Review | Prevention of venous thromboembolism in patients with cancer
5 Jun, 2023 | 13:48h | UTCPrevention of venous thromboembolism in patients with cancer – The BMJ
RCT | Osimertinib improves overall survival in resected EGFR-mutated NSCLC, but validity of control group questioned on social media
5 Jun, 2023 | 13:46h | UTCOverall Survival with Osimertinib in Resected EGFR-Mutated NSCLC – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter by Dr. Vinay Prasad (recommended – click to see the video)
Here is the REAL @Plenary_Session on #ADAURA #ASCO23 #ASCO2023
38.5% of people who had recurrence got OSI (very low!)
That just isn't good enough
Brain staging is suboptimal= occult met disease
Would you let your mother be on the control arm and not get OSI on progression? pic.twitter.com/CU3jtrvFOj— Vinay Prasad MD MPH (@VPrasadMDMPH) June 5, 2023
#ASCO23 – RCT | Simple hysterectomy shown non-inferior to radical hysterectomy in low-risk early-stage cervical cancer
5 Jun, 2023 | 13:43h | UTCCommentaries:
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050
2 Jun, 2023 | 12:34h | UTCEditorial: The global epidemic of low back pain – The Lancet Rheumatology
News Releases:
Commentary on Twitter
NEW—GBD 2021 data published in @TheLancetRheum finds low back pain is the leading cause of disability globally. #LowBackPain affects 619 million individuals (1 out of every 13 people). More women across all age groups suffered from low back pain than men.https://t.co/A2RoU9hn9p pic.twitter.com/vhXwcVh1e7
— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) May 22, 2023
ACR Guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis
2 Jun, 2023 | 12:33h | UTCNews Release: New Guideline Introduces Recommendations for Integrative Approach to RA Treatment – American College of Rheumatology
M-A | Coronary revascularization in HF and CAD: a small but significant effect on mortality
2 Jun, 2023 | 12:31h | UTC
Quality-improvement intervention | Impact of stopping preoperative screening for asymptomatic bacteriuria
2 Jun, 2023 | 12:29h | UTCCommentary: Hospital intervention reduces unnecessary screening, antibiotics for bacteriuria – CIDRAP
Systematic Review | Bupropion and nortriptyline: an assessment of their effectiveness in smoking cessation
2 Jun, 2023 | 12:28h | UTCAntidepressants for smoking cessation – Cochrane Library
ASH 2023 Guidelines for management of venous thromboembolism | Thrombophilia testing
1 Jun, 2023 | 12:22h | UTC
AASLD-IDSA Guideline | Updated 2023 recommendations for the testing, management, and treatment of Hepatitis C virus infection
1 Jun, 2023 | 12:21h | UTC
RCT | Dupilumab improves lung function and reduces exacerbations in COPD patients with elevated eosinophils
1 Jun, 2023 | 12:20h | UTCDupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Dupilumab Improves Outcomes for COPD, Type 2 Inflammation in Randomized Trial – HCP Live
Commentary on Twitter
Presented at #ATS2023: In the BOREAS trial, dupilumab resulted in a lower annualized rate of exacerbations than placebo among patients with COPD and an elevated blood eosinophil count. Full trial results: https://t.co/9IWZr3YqsN
— NEJM (@NEJM) May 21, 2023
SR | Individual‐level interventions for reducing occupational stress in healthcare workers
1 Jun, 2023 | 12:18h | UTCNews Release: Stress-management interventions may help individual healthcare workers for at least a year – Cochrane Library